Skip to Content
Merck

1344702

USP

Iopamidol

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

(S)-N,N′-Bis[2-hydroxy-1-(hydroxymethyl)ethyl]-2,4,6-triiodo-5-lactamidoisophthalamide

Slide 1 of 1
Sign In to View Organizational & Contract Pricing.

Select a Size

200 MG

PLN 1,910.00

PLN 1,910.00

Please contact Customer Service for Availability
​
Request a Bulk Order

About This Item

Empirical Formula (Hill Notation):
C17H22I3N3O8
CAS Number:
60166-93-0
Molecular Weight:
777.09
MDL number:
MFCD00867931
UNSPSC Code:
41116107
NACRES:
NA.24

Key Documents

View All Documentation

Skip To

Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

grade

pharmaceutical primary standard

API family

iopamidol

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

Ic1c(c(c(c(c1C(=O)NC(CO)CO)I)C(=O)NC(CO)CO)I)NC(=O)[C@@H](O)C

InChI

1S/C17H22I3N3O8/c1-6(28)15(29)23-14-12(19)9(16(30)21-7(2-24)3-25)11(18)10(13(14)20)17(31)22-8(4-26)5-27/h6-8,24-28H,2-5H2,1H3,(H,21,30)(H,22,31)(H,23,29)/t6-/m0/s1

InChI key

XQZXYNRDCRIARQ-LURJTMIESA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
I03290001344724PHR1985
USP

USP

1344702

Iopamidol

vibrant-m

I0329000

Iopamidol

USP

USP

1344724

Iopamidol Related Compound A

Iopamidol Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1985

Iopamidol

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

certified reference material, pharmaceutical secondary standard

manufacturer/tradename

USP

manufacturer/tradename

EDQM

manufacturer/tradename

USP

manufacturer/tradename

-

format

neat

format

neat

format

neat

format

-

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical

API family

iopamidol

API family

iopamidol

API family

iopamidol

API family

-

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Iopamidol USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Iopamidol Injection

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

Storage Class

11 - Combustible Solids

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Tomonori Kanda et al.
PloS one, 10(2), e0118317-e0118317 (2015-02-24)
Double hypoglossal canal, namely a hypoglossal canal bridging, is a normal variation of the hypoglossal canal. Racial differences in the prevalence of double hypoglossal canal have been reported. We evaluated the prevalence of double hypoglossal canal in a Japanese population
Kiyoko Yoshino et al.
Hepatology research : the official journal of the Japan Society of Hepatology, 44(11), 1088-1094 (2013-09-17)
Although rupture of rectal varices is rarely encountered, it may provoke massive and fatal hemorrhage in patients with liver cirrhosis. We examined the clinical features of patients showing bleeding from rectal varices to establish a suitable therapeutic strategy for the
Shigeo Horinaka et al.
Atherosclerosis, 235(1), 239-245 (2014-05-28)
The cardio-ankle vascular index (CAVI) is an arterial stiffness index based on the stiffness parameter β, which is essentially independent of blood pressure. The objective of this study was to determine whether CAVI correlates with the regional stiffness parameter β
Karla Maria Treitl et al.
Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists, 22(1), 63-70 (2015-03-17)
To prospectively assess current limitations and complication rates of the transbrachial access technique for endovascular treatment of peripheral vascular pathologies. In total, 150 patients (112 men; mean age 66.3 ± 10.0 years) with arterial occlusive disease underwent endovascular therapy via
Fereshteh Hajsadeghi et al.
Atherosclerosis, 237(2), 486-489 (2014-12-03)
Increased-epicardial-adipose tissue (EAT) is associated with the presence and severity of subclinical-atherosclerosis. This study investigates the long-term clinical-outcome of subjects with and without increased-EAT. Two hundred and forty-five subjects, aged 61 ± 9 years and 34% women underwent clinically-indicated computed-tomography-angiography
View All Related Papers

Global Trade Item Number

SKUGTIN
1344702-200MG04061838730107

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service